Today: 15 May 2026
Why AppLovin stock is surging today: CapitalWatch retracts claims as Jefferies backs APP ahead of earnings
9 February 2026
2 mins read

Why AppLovin stock is surging today: CapitalWatch retracts claims as Jefferies backs APP ahead of earnings

New York, February 9, 2026, 11:41 (ET) — Regular session

  • AppLovin shares jumped roughly 14% in late-morning trading, following a publisher’s decision to retract portions of a critical report.
  • James Heaney at Jefferies stuck with his Buy rating and held the $860 price target. He called the selloff a “great buying opportunity.”
  • Attention now turns to AppLovin’s Feb. 11 report, with investors listening closely for management’s take on growth prospects and looming risks.

AppLovin Corp got a lift Monday, with shares climbing after CapitalWatch pulled back sections of a previous report that linked the marketing platform to money laundering. The move helped clear up some of the uncertainty that’s been weighing on the stock.

This rebound is notable. AppLovin stands out as one of this year’s more volatile U.S. software names, with investors swinging between optimism on growth and nerves over headlines. Earnings are out in two days; expectations for trust and guidance are running higher than normal.

This comes as software names have been on a rollercoaster, with investors questioning if rapid-fire AI innovation might upend how software companies make money—or how they’re valued.

AppLovin (APP.O) surged 13.7% to $462.54, building on Friday’s close of $406.72. At its peak this session, shares reached $464.98.

Barron’s noted that CapitalWatch has issued a correction and apology to major shareholder Hao Tang, admitting that certain descriptions “were inaccurate and failed to meet our publication standards.” Still, the outlet pointed to lingering questions about AppLovin’s “complex financial structure.” According to the report, CapitalWatch is lining up further articles focused on data-security risks, as well as revenue and “return on ad spend” metrics — essentially, how much advertisers recoup for every dollar they put in. https://www.barrons.com/articles/applovin-…

Palo Alto’s AppLovin makes software for advertisers looking to buy ads, and for app publishers aiming to monetize users. The stock, weighed down since January, has struggled after the initial CapitalWatch report.

Jefferies’ James Heaney doubled down on his bullish view Monday, sticking with a Buy and his $860 target. The analyst described the stock’s drop this year as “a great buying opportunity,” arguing that competitive concerns and ad-network jitters are now “overblown risks.” For Heaney, valuation stands out—roughly 15x his projected fiscal 2027 EBITDA, a standard stand-in for cash profit. He’s looking for “a significant revenue beat” in Q4. https://www.investing.com/news/stock-marke…

A catalyst looms for the company. AppLovin will drop its fourth-quarter and full-year 2025 numbers after the U.S. close on Wednesday, Feb. 11. CEO Adam Foroughi and CFO Matthew Stumpf are set to run a webcast at 5:00 p.m. ET. Full details here:

Still, the relief rally might not hold. Traders face the possibility of further negative research, renewed scrutiny on data and ad metrics, and a real risk that earnings or guidance won’t do much to restore confidence.

AppLovin heads into Wednesday’s report and call with investors focused on the basics: they want to see clean numbers, some sign of stable demand, and specifics—if there are any—addressing the recent controversy.

Stock Market Today

  • RenovoRx Q1 Loss Matches Estimates, Revenue Beats Expectations
    May 14, 2026, 6:48 PM EDT. RenovoRx, Inc. (RNXT) reported a first-quarter loss of $0.08 per share, aligning with Zacks Consensus Estimates. Revenue came in at $0.56 million, exceeding estimates by 12.6% and showing growth from $0.2 million a year ago. The company has missed EPS estimates over the past year but outperformed revenue forecasts twice in four quarters. Despite this, RNXT shares have gained only around 1% year-to-date, compared to the S&P 500's 8.8% rise. The stock holds a Zacks Rank #3 (Hold), indicating expected market-line performance ahead. Investors will watch management's commentary and revisions to earnings forecasts closely, given the Medical - Biomedical and Genetics industry ranks in the bottom 41% among 250 industries by Zacks.

Latest articles

Amazon Stock Falls Today: Why AMZN Slipped While Tech Hit Fresh Highs

Amazon Stock Falls Today: Why AMZN Slipped While Tech Hit Fresh Highs

15 May 2026
Amazon shares fell 1.1% to $267.22 on Thursday, underperforming record highs in the S&P 500 and Nasdaq. Investors focused on Amazon’s rising AI and cloud spending, with little expectation of relief from lower U.S. rates. First-quarter revenue rose 17% to $181.5 billion, but free cash flow dropped sharply due to higher capital spending.
Unusual Machines Stock Jumps As Q1 Revenue Nearly Quadruples And Drone Supply Bet Widens

Unusual Machines Stock Jumps As Q1 Revenue Nearly Quadruples And Drone Supply Bet Widens

15 May 2026
Unusual Machines reported first-quarter revenue of $8.1 million, up 296% from a year earlier, and net income of $10.3 million driven by investment gains despite an operating loss. Shares rose 12.8% to $16.93 after the results. The company raised $150 million in equity and agreed to buy battery maker DroneNX for up to $52 million. Headcount rose to over 190 as of Thursday.
Microsoft Stock Rises As AI Trade Reignites: Why MSFT Shares Moved Today

Microsoft Stock Rises As AI Trade Reignites: Why MSFT Shares Moved Today

15 May 2026
Microsoft shares rose 1.04% to $409.43 on Thursday as investors favored large tech stocks amid record highs for the S&P 500 and Nasdaq. Microsoft reported March-quarter revenue up 18% to $82.9 billion, with Azure and cloud services up 40%. The company expects $190 billion in capital expenditures this year, well above analyst estimates. Microsoft is also exploring AI startup deals as it reassesses its reliance on OpenAI.
United States Antimony Stock Falls After $11.3 Million Loss as Defense Contract Ramp Awaits

United States Antimony Stock Falls After $11.3 Million Loss as Defense Contract Ramp Awaits

15 May 2026
United States Antimony posted a first-quarter net loss of $11.3 million, or 8 cents a share, on $6.8 million in revenue, down from a $546,524 profit a year earlier. Shares fell about 4% to $9.57 in late trading. The company completed initial deliveries under a $245 million Defense Logistics Agency contract but did not recognize revenue from it in the quarter. Gross profit dropped to $1.1 million from $2.4 million.
Intuitive Machines stock jumps 13% in heavy trade as LUNR stays a lightning rod
Previous Story

Intuitive Machines stock jumps 13% in heavy trade as LUNR stays a lightning rod

MercadoLibre stock pops back over $2,000 as MELI eyes Feb. 24 results
Next Story

MercadoLibre stock pops back over $2,000 as MELI eyes Feb. 24 results

Go toTop